Login / Signup

Real-world data with the use of caplacizumab in the treatment of acquired thrombotic thrombocytopenic purpura: A single-center with homogeneous treatment experience.

Moraima JiménezSabela BobilloVerónica PonsCarla SánchezAna PérezAntonieta MoleroNayibe MirandaÁngela SánchezElizabeth TabaresFrancesc BoschDavid Valcárcel
Published in: Transfusion (2022)
Our experience confirms improvement in the outcomes with a decrease in refractoriness and mortality since the introduction of caplacizumab.
Keyphrases
  • cardiovascular events
  • metabolic syndrome
  • adipose tissue
  • big data
  • replacement therapy
  • smoking cessation
  • glycemic control